BioSpace News Archive

Orexo AB, the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, announces it has appointed Dennis Urbaniak as Executive Vice President of Digital Health.

18 month project in collaboration with University of Leeds and Medicines Discovery Catapult will deliver a new compound for treatment of thrombosis

Shape Memory Medical Inc. announced that its IMPEDE® Embolization Plugs have been approved in Japan by the Pharmaceuticals and Medical Devices Agency.

IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the closing of a $55.5 million financing and the launch of its third subsidiary, IFM Quattro, as well as a new incubator, IFM Discovery, both of which will be supported by a portion of the new funds raised.

Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical stage biopharmaceutical company, today announced positive top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating the efficacy and safety of its lead product candidate Amphora® for the prevention of urogenital chlamydia and gonorrhea in women.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, chief marketing officer for Merck is scheduled to present during a fireside chat at the Evercore ISI HealthCONx Conference in Boston on Dec. 4, 2019 at 2:00 p.m. EST.

Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces it has been invited to present the performance of its in-vitro diagnostics (IVD) quality products “IVD Controls” at EUROGIN 2019, the annual congress of the European Research Organization on Genital Infection & Neoplasia.

Bhang Inc. (“Bhang” or the “Company”) (CSE: BHNG) (OTCQX: BHNGF), a global cannabis CPG brand company with an extensive, award-winning portfolio of products, today reported its financial and operating results for the third quarter ending September 30, 2019.

Company intends to meet with FDA shortly to discuss planned regulatory submission and potential clearance pathway

Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that it received a letter dated November 27, 2019 from the Listing Qualifications Department of The Nasdaq Stock Market LLC